IFNA2 and type 1 diabetes mellitus: While there is clear evidence that type I IFNs can modulate pathogenic autoimmune responses, it is important to know how systemic IFNα activity might promote cell-type specific effects in diseased versus nondiseased tissues in disorders like T1D that target a particular tissue, but also in diseases like SLE that have multi-organ effects.